Loading...
Market
What major milestone will Radionetics achieve by end of 2024?
2
Resolution / Starting Odds
New clinical trial initiation • 25%
Partnership with another pharma company • 25%
FDA approval • 25%
Acquisition by Lilly • 25%
Official announcements from Radionetics Oncology
Story
Radionetics Oncology Enters $140M Strategic Agreement With Lilly, Acquisition Option for $1B
Jul 1, 2024, 02:51 PM
Radionetics Oncology has entered into a strategic agreement with Eli Lilly and Company. As part of the deal, Radionetics will receive a $140 million upfront payment. In return, Lilly gains the exclusive right to acquire Radionetics for $1 billion. The agreement focuses on enhancing Lilly's cancer drug pipeline with radiopharmaceuticals developed by Radionetics. Lilly inks the deal with the biotech startup to expand its radiopharmaceutical offerings.
View original story
Similar markets
Progress to Phase 2 • 25%
Significant efficacy results • 25%
Safety concerns emerge • 25%
No significant milestone • 25%
Discovery of a new neuro-target • 25%
Publication in a top-tier journal • 25%
FDA approval for a related treatment • 25%
Other • 25%
Successful autonomous navigation in open waters • 25%
Integration with U.S. Navy's existing systems • 25%
Completion of first production-ready ASV • 25%
Other • 25%
Phase 1 completion • 25%
Phase 2 completion • 25%
Phase 3 completion • 25%
No significant milestone • 25%
Achieve 1 million error-free quantum operations • 25%
Develop next-generation chip • 25%
Expand semiconductor production • 25%
Other • 25%
FDA approval for commercial use • 25%
Integration with another major tech device • 25%
Partnership with a major tech company • 25%
Clinical trials expansion • 25%
Start of Phase 3 trial • 33%
FDA approval • 33%
Partnership announcement • 33%
Yes • 50%
No • 50%
Completion of site investigations • 25%
Submission of application under the ADVANCE Act • 25%
Approval of application under the ADVANCE Act • 25%
No major milestone achieved • 25%